AstraZeneca Set For Boston Area Growth Spurt
This article was originally published in The Pink Sheet Daily
Executive Summary
$100 million expansion will add 132,000 square feet of lab space for research in infectious disease and cancer by 2009.
You may also be interested in...
Genentech Kicks Off New Year With Exelixis Deal For MEK Inhibitor
Genentech joins Pfizer and AstraZeneca in developing the new class of oncology compounds.
AstraZeneca Acquires Asian Rights To Cubist’s Antibiotic Cubicin
Cubist is in talks with potential partners for Japanese rights, which the firm has retained.
Bristol To Break Ground On New Biologics Facility In September
The Devens, Mass. facility will allow the firm to increase production of the rheumatoid arthritis product Orencia (abatacept).